$2.43 Billion is the total value of SECTORAL ASSET MANAGEMENT INC's 64 reported holdings in Q1 2014. The portfolio turnover from Q4 2013 to Q1 2014 was 46.2% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
AMGN | Buy | AMGEN INC | $173,300,000 | +20.3% | 1,405,062 | +11.3% | 7.13% | +14.8% |
GILD | Buy | GILEAD SCIENCES INC | $145,788,000 | -0.0% | 2,057,416 | +6.0% | 6.00% | -4.6% |
TMO | Buy | THERMO FISHER SCI | $94,449,000 | +64.2% | 785,500 | +52.1% | 3.88% | +56.6% |
REGN | Buy | REGENERON PHARMCTCLS | $92,306,000 | +21.5% | 307,400 | +11.4% | 3.80% | +15.9% |
VRTX | Buy | VERTEX PHARMACEUTICL | $90,291,000 | -1.4% | 1,276,741 | +3.6% | 3.71% | -5.9% |
ALXN | Buy | ALEXION PHARM INC | $83,368,000 | +26.4% | 548,008 | +10.4% | 3.43% | +20.6% |
TEVA | Buy | TEVA PHARMACEUTICALadr | $76,195,000 | +209.8% | 1,441,992 | +135.0% | 3.13% | +195.4% |
INCY | Buy | INCYTE CORPORATION | $75,097,000 | +25.1% | 1,403,160 | +18.4% | 3.09% | +19.4% |
HALO | Buy | HALOZYME THERAPEUTIC | $68,041,000 | -3.5% | 5,355,488 | +13.9% | 2.80% | -7.9% |
MYL | Buy | MYLAN INC | $67,908,000 | +14.3% | 1,390,697 | +1.6% | 2.79% | +9.0% |
BMRN | Buy | BIOMARIN PHARMAC INC | $63,258,000 | +26.0% | 927,406 | +29.9% | 2.60% | +20.1% |
KERX | Buy | KERYX BIOPHARMACEUT | $60,281,000 | +68.7% | 3,537,590 | +28.2% | 2.48% | +60.9% |
IMGN | Buy | IMMUNOGEN INC | $54,103,000 | +5.0% | 3,623,786 | +3.1% | 2.22% | +0.1% |
OMED | Buy | ONCOMED PHARMACEUT | $45,348,000 | +25.9% | 1,347,642 | +10.5% | 1.86% | +20.1% |
AEGR | New | AEGERION PHARMACEU | $43,137,000 | – | 934,100 | +100.0% | 1.77% | – |
ILMN | Buy | ILLUMINA INC | $36,420,000 | +56.3% | 244,989 | +16.3% | 1.50% | +49.1% |
CLVS | Buy | CLOVIS ONCOLOGY | $34,178,000 | +20.0% | 493,400 | +4.4% | 1.41% | +14.5% |
PTLA | Buy | PORTOLA PHARMACEUTIC | $31,397,000 | +21.7% | 1,212,245 | +21.0% | 1.29% | +16.1% |
FRX | New | FOREST LABS INC | $24,922,000 | – | 270,100 | +100.0% | 1.02% | – |
PTCT | Buy | PTC THERAPEUTICS I | $24,778,000 | +2438.7% | 947,902 | +1548.0% | 1.02% | +2326.2% |
ICPT | New | INTERCEPT PHARMACE | $24,567,000 | – | 74,493 | +100.0% | 1.01% | – |
SGNT | Buy | SAGENT PHARMACEUTI | $24,270,000 | +38.6% | 1,038,504 | +50.6% | 1.00% | +32.2% |
UTHR | Buy | UNITED THERAPEUTICS | $22,041,000 | +7.1% | 234,400 | +28.8% | 0.91% | +2.1% |
SGEN | Buy | SEATTLE GENETICS INC | $20,175,000 | +19.7% | 442,819 | +4.8% | 0.83% | +14.2% |
VRX | New | VALEANT PHARMA INTL | $16,980,000 | – | 128,800 | +100.0% | 0.70% | – |
MNTA | Buy | MOMENTA PHARMACEUTIC | $12,941,000 | -18.2% | 1,110,797 | +24.2% | 0.53% | -22.0% |
NVO | Buy | NOVO-NORDISK ASadr | $6,236,000 | +67.7% | 136,610 | +578.8% | 0.26% | +60.6% |
INGN | New | INOGEN INC | $4,679,000 | – | 283,410 | +100.0% | 0.19% | – |
NVS | Buy | NOVARTIS AGsp adr | $2,653,000 | +172.7% | 31,200 | +157.9% | 0.11% | +159.5% |
EBIO | New | ELEVEN BIOTHERAPEU | $812,000 | – | 50,000 | +100.0% | 0.03% | – |
ANTH | New | ANTHERA PHARMACEUT | $742,000 | – | 221,462 | +100.0% | 0.03% | – |
GLYC | New | GLYCOMIMETICS INC | $728,000 | – | 44,587 | +100.0% | 0.03% | – |
TNDM | Buy | TANDEM DIABETES CA | $665,000 | +29.1% | 30,100 | +50.5% | 0.03% | +22.7% |
FPRX | New | FIVE PRIME THERAPE | $636,000 | – | 32,372 | +100.0% | 0.03% | – |
LPTN | New | LPATH INC | $601,000 | – | 126,464 | +100.0% | 0.02% | – |
TKMR | New | TEKMIRA PHARMACEU | $591,000 | – | 27,500 | +100.0% | 0.02% | – |
AQXP | New | AQUINOX PHARMACEUT | $382,000 | – | 30,000 | +100.0% | 0.02% | – |
WX | Buy | WUXI PHAR ADSsp adr | $247,000 | +7.4% | 6,690 | +11.5% | 0.01% | 0.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-05-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
BIOMARIN PHARMAC INC | 42 | Q3 2023 | 6.7% |
PTC THERAPEUTICS INC | 42 | Q3 2023 | 2.7% |
DR REDDYS LABS LTD | 42 | Q3 2023 | 2.0% |
GILEAD SCIENCES INC | 38 | Q3 2023 | 8.4% |
INCYTE CORPORATION | 38 | Q3 2023 | 5.2% |
VERTEX PHARMACEUTICL | 38 | Q3 2023 | 6.0% |
AMICUS THERAPEUTICS INC | 37 | Q3 2023 | 6.6% |
PFIZER INC | 35 | Q3 2023 | 6.3% |
MERCK & CO. INC | 34 | Q3 2023 | 6.4% |
MEDTRONIC PLC | 33 | Q3 2023 | 4.4% |
View SECTORAL ASSET MANAGEMENT INC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Aprea Therapeutics, Inc. | February 12, 2021 | 163,681 | 0.8% |
LA JOLLA PHARMACEUTICAL CO | February 13, 2020 | ? | ? |
COLLEGIUM PHARMACEUTICAL, INC | February 13, 2018 | 1,426,862 | 4.4% |
Advaxis, Inc. | February 10, 2017 | 690,074 | 1.7% |
AMICUS THERAPEUTICS INC | February 10, 2017 | 5,100,198 | 3.6% |
OncoMed Pharmaceuticals Inc | February 12, 2016 | ? | ? |
IRONWOOD PHARMACEUTICALS INC | February 13, 2015 | ? | ? |
SEQUENOM INC | February 12, 2014 | ? | ? |
INCYTE CORP | February 11, 2014 | 1,185,260 | 0.7% |
INTERMUNE INC | February 11, 2014 | ? | ? |
View SECTORAL ASSET MANAGEMENT INC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-11 |
13F-HR | 2023-05-12 |
SC 13G/A | 2023-02-13 |
SC 13G | 2023-02-13 |
13F-HR | 2023-02-10 |
13F-HR | 2022-11-10 |
View SECTORAL ASSET MANAGEMENT INC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.